FDA to decide on Johnson & Johnson vaccine

The corporation is set to meet with a panel from the Federal Drug Administration for emergency use authorization of its single-shot vaccine, which could be approved as early as Friday evening.
3:06 | 02/26/21

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:



Skip to this video now

Now Playing:


Related Extras
Related Videos
Video Transcript
Transcript for FDA to decide on Johnson & Johnson vaccine
Now to the latest on the fight against the coronavirus emergency. So far 46 million americansave received at least one dose of the vaccine that is nearly 14% of the country and the fda could grant emergency use authorization to another covid vaccine in just hours. Take a live look at the Johnson & Johnson storage facility in Kentucky where the one-dose vaccine is ready to go. Steve osunsami is live now outside CDC headquarters in Atlanta with more this morning. Good morning, Steve. Reporter: Good morning to you, Michael. Here at the CDC they believe that about 20 million Americans have now been fully vaccinated against covid-19. Those are people who have gotten both shots of the two-shot vaccine. This one-shot vaccine will make it much easier to vaccinate more people. A third covid vaccine could be available to Americans next week and this one has been tested against the number of variants of the coronavirus that have been worrying public health officials. Johnson & Johnson has come up with a single-shot vaccine and today they have an all day hearing with the panel from the fda. As early as this evening the government could say yes to emergency use authorization of the drug. The drugmaker says they can ship up to 4 million doses across the country as soon as the fda gives the okay. Just like the modern and pfizer vaccines, those first Johnson & Johnson doses will be divided up based on population between 64 areas. If the fda approves the use of this new vaccine, we have a plan to roll it out as quickly as Johnson & Johnson can make Reporter: The Johnson & Johnson vaccine appears highly effective against the coronavirus. The company reports that it is 85% effective against preventing severe illness and 100% effective against hospitalization and death. By the end of June it's now possible we could have enough vaccine supply for all of America. Johnson & Johnson expects to produce 100 million single-dose vaccines covering 100 million people. Moderna and pfizer both two-dose vaccines expect to produce 600 million doses covering 300 million people. That's more than enough to vaccinate every American adult by the end of summer, a goal set by the president. Across America about 66 million doses of the two-dose vaccines have been put into arms and about 50 million of those shots have happened since president Biden took office. The president's goal was 100 million shots in his first 100 days in office. And with one month in, he's already half the way there. But he still says he's not celebrating yet. While things are improving this is not a victory lap. Everything is not fixed. Reporter: What could help even more are more vaccines and there are possibly two more coming soon. The oxford astrazeneca and novavax vaccine are in phase 3 trials. At the very latest, public health officials are hoping that the emergency use authorization for the Johnson & Johnson vaccine is granted by this weekend. George. Okay, Steve, thanks.

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"3:06","description":"The corporation is set to meet with a panel from the Federal Drug Administration for emergency use authorization of its single-shot vaccine, which could be approved as early as Friday evening.","mediaType":"default","section":"ABCNews/GMA","id":"76131673","title":"FDA to decide on Johnson & Johnson vaccine","url":"/GMA/News/video/fda-decide-johnson-johnson-vaccine-76131673"}